EA201501054A1 - Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы - Google Patents

Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы

Info

Publication number
EA201501054A1
EA201501054A1 EA201501054A EA201501054A EA201501054A1 EA 201501054 A1 EA201501054 A1 EA 201501054A1 EA 201501054 A EA201501054 A EA 201501054A EA 201501054 A EA201501054 A EA 201501054A EA 201501054 A1 EA201501054 A1 EA 201501054A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tragose
myopathies
parental
proteins
introduction
Prior art date
Application number
EA201501054A
Other languages
English (en)
Inventor
Далиа Мегиддо
Original Assignee
Био Бласт Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Био Бласт Фарма Лтд. filed Critical Био Бласт Фарма Лтд.
Publication of EA201501054A1 publication Critical patent/EA201501054A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предлагает способ лечения болезни, связанной с аномальной агрегацией белков, состоящий в парентеральном введении фармацевтических составов, содержащих трегалозу. Также изобретение предлагает применять инъекционный водный фармацевтический состав, содержащий терапевтически эффективное количество трегалозы.
EA201501054A 2013-05-07 2014-05-07 Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы EA201501054A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Publications (1)

Publication Number Publication Date
EA201501054A1 true EA201501054A1 (ru) 2016-04-29

Family

ID=51022384

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201501054A EA201501054A1 (ru) 2013-05-07 2014-05-07 Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы

Country Status (15)

Country Link
US (4) US10493023B2 (ru)
EP (2) EP4218769A3 (ru)
JP (4) JP6837835B2 (ru)
KR (1) KR20160009617A (ru)
AU (4) AU2014264228A1 (ru)
CA (2) CA3239805A1 (ru)
CR (1) CR20150637A (ru)
EA (1) EA201501054A1 (ru)
HK (1) HK1217300A1 (ru)
IL (1) IL241757B (ru)
MD (1) MD20150120A2 (ru)
MX (1) MX2015015355A (ru)
PE (1) PE20160012A1 (ru)
SG (1) SG11201509030TA (ru)
WO (1) WO2014181333A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
EA201501054A1 (ru) 2013-05-07 2016-04-29 Био Бласт Фарма Лтд. Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
CA3012502A1 (en) * 2016-02-08 2017-08-17 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
US10512656B2 (en) 2016-04-21 2019-12-24 Baylor College Of Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
US11844808B2 (en) 2018-01-16 2023-12-19 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
WO2021161319A1 (en) * 2020-02-13 2021-08-19 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2022013940A1 (ja) * 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
WO2024118797A1 (en) * 2022-11-30 2024-06-06 Seelos Therapeutics, Inc. Trehalose for treating huntington's disease

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS516109B2 (ru) 1972-12-28 1976-02-25
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
WO1997024129A1 (en) 1995-12-27 1997-07-10 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
EP1578394A4 (en) * 2002-12-31 2011-02-23 Nektar Therapeutics ANTIBODY PARTICLES AND COMPOSITIONS
US7854922B2 (en) 2003-02-13 2010-12-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Skin preparation for external use characterized by containing sugar derivative of α, α-trehalose
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CA2608198A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
CN101232891A (zh) 2005-08-11 2008-07-30 株式会社林原生物化学研究所 胶原产生增强剂及其用途
WO2007063902A1 (ja) 2005-11-30 2007-06-07 The Nisshin Oillio Group, Ltd. トレハロース脂肪酸エステル組成物
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
WO2007111214A1 (ja) 2006-03-27 2007-10-04 Otsuka Chemical Co., Ltd. トレハロース化合物および該化合物を含有する医薬
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
WO2008093700A1 (ja) 2007-01-31 2008-08-07 Otsuka Chemical Co., Ltd. トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤
WO2008102563A1 (ja) 2007-02-23 2008-08-28 Next21 K.K. 血管攣縮の治療剤又は予防剤
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EA201070544A1 (ru) 2007-10-31 2010-12-30 Диффьюжн Фармасьютикалз Ллс Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
JP5552056B2 (ja) 2008-10-31 2014-07-16 株式会社糖鎖工学研究所 トレハロース化合物、その製造方法、及び該化合物を含有する医薬
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
WO2012061907A2 (en) * 2010-11-10 2012-05-18 Katholieke Universiteit Leuven Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
EA201501054A1 (ru) 2013-05-07 2016-04-29 Био Бласт Фарма Лтд. Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof

Also Published As

Publication number Publication date
KR20160009617A (ko) 2016-01-26
CA3239805A1 (en) 2014-11-13
US20190374463A1 (en) 2019-12-12
HK1217300A1 (zh) 2017-01-06
JP2016518403A (ja) 2016-06-23
US10493023B2 (en) 2019-12-03
US20220117883A1 (en) 2022-04-21
WO2014181333A2 (en) 2014-11-13
WO2014181333A3 (en) 2015-01-08
MX2015015355A (es) 2016-07-18
US20160120798A1 (en) 2016-05-05
AU2020277197A1 (en) 2020-12-24
IL241757B (en) 2020-05-31
AU2019204513B2 (en) 2020-09-10
CR20150637A (es) 2016-04-05
SG11201509030TA (en) 2015-11-27
AU2019204513A1 (en) 2019-07-18
AU2014264228A1 (en) 2015-11-12
US20240009113A1 (en) 2024-01-11
JP2023040211A (ja) 2023-03-22
PE20160012A1 (es) 2016-02-14
EP2994145B1 (en) 2023-01-04
EP2994145A2 (en) 2016-03-16
JP6837835B2 (ja) 2021-03-03
JP2021152032A (ja) 2021-09-30
EP4218769A3 (en) 2023-10-18
JP2019142907A (ja) 2019-08-29
MD20150120A2 (ru) 2016-03-31
US10869831B2 (en) 2020-12-22
CA2911399A1 (en) 2014-11-13
AU2023200303A1 (en) 2023-02-23
EP4218769A2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
BR112017005736A2 (pt) macrociclos peptidomiméticos e formulações dos mesmos
MX2019007351A (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201791333A1 (ru) Производные глюкагона с улучшенной стабильностью
EA201591535A1 (ru) Замещенные производные 3-фенилпропиламина для лечения офтальмологических заболеваний и расстройств
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201992772A1 (ru) Инъецируемые препараты длительного действия, содержащие изоксазолиновое действующее вещество, способы и применение
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний